4//SEC Filing
Ostertag Eric 4
Accession 0001209191-22-045296
CIK 0001661460other
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 6:13 PM ET
Size
9.0 KB
Accession
0001209191-22-045296
Insider Transaction Report
Form 4
Ostertag Eric
DirectorChief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2022-08-08$3.50/sh+142,857$500,000→ 838,824 total
Holdings
- 3,659,503(indirect: See footnote)
Common Stock
- 580,292(indirect: See footnote)
Common Stock
- 3,358,455(indirect: See footnote)
Common Stock
- 961,445(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with sales effected on August 3, 2022 pursuant to a Rule 10b5-1 trading plan established independently of the reporting person by Transposagen Biopharmaceuticals and in connection with a planned dissolution of Transposagen Biopharmaceuticals. The reporting person will disgorge the full amount of any recoverable profits to the Issuer.
- [F2]The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
- [F3]The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- [F4]The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
- [F5]The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
Documents
Issuer
Poseida Therapeutics, Inc.
CIK 0001661460
Entity typeother
Related Parties
1- filerCIK 0001765987
Filing Metadata
- Form type
- 4
- Filed
- Aug 9, 8:00 PM ET
- Accepted
- Aug 10, 6:13 PM ET
- Size
- 9.0 KB